HOME >> BIOLOGY >> NEWS
Report in Science on x-ray crystal structure of matrix Metalloproteinase-2 (MMP-2)

MMP-2 is a key target for anti-cancer drug development

Research Triangle Park, N.C.--June 4, 1999-- BioStratum Incorporated announced today the publication of a paper in the journal SCIENCE (volume 284, pages 1667-1670) reporting the three-dimensional structure of the matrix metalloproteinase-2 (MMP-2), a key molecular target for a number of anti-cancer drug candidates currently in clinical development. This work was completed by one of BioStratum's founding scientists, Dr. Karl Tryggvason of the Karolinska Institute, Stockholm, Sweden.

The elucidated structure of MMP-2 provides valuable information on the function and regulation of this important enzyme, and provides for the design of improved MMP-2 specific inhibitors for clinical evaluation. BioStratum owns intellectual property rights to this technology and to new and improved MMP-2 inhibitors that may be identified.

Matrix metalloproteinases (MMPs) are involved in tissue growth and wound repair. MMPs work by degrading substances in the extracellular matrix (the area outside of cells) thereby enabling the movement and expansion of cells, the deposition of new extracellular matrix, and the subsequent development of new tissue. MMP-2 acts directly on type IV collagen, a principal component of the basal lamina, a specialized form of the extracellular matrix. The activation of MMPs has been implicated in the invasive growth and spread of tumors. Several clinical studies are in progress evaluating the effectiveness of MMP inhibitors as anti-cancer agents, and many more are projected to enter clinical trials in the near future.

The elucidated molecular structure is the culmination of seven years of effort in Dr. Tryggvason?s laboratory. "This advance is providing important insights into the catalytic and regulatory mechanisms of this enzyme. It also provides an additional tool to aid in the design of improved MMP inhibitors to combat the spread of cancer," said Dr. Tryggvason.<
'"/>

Contact: J. Wesley Fox, Ph.D.
info@biostratum.com
919-572-6515
Noonan/Russo Communications
4-Jun-1999


Page: 1 2 3

Related biology news :

1. Report outlines vision and recommendations for microbiology in the 21st Century
2. Report outlines steps needed to lessen smallpox threat
3. Reporters from Science Magazine to receive ASM Public Communications Award
4. Report in BioScience details global decline of nonmarine mollusks
5. National Academies news: Report on EPAs particulate matter research
6. Report details growing climate change threat to coral reefs
7. Report to aid nation in managing freshwaters
8. Report examines use of antibiotics in agriculture
9. Report offers action plan for curbing diseases that kill millions
10. Report focuses on the science and safety of genetically modified crops
11. Report considers role of science in a world made vulnerable by terrorism

Post Your Comments:
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/31/2015)... 2015  Sonoa Health, a health tech startup based ... a world-first consumer health portal, Health&, which brings together ... and more. Today, the Company appointed respected ... who brings to the table more than 18-years experience ... working closely with the biggest names in Silicon Valley ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 /PRNewswire/ ... biopharmaceutical company advancing protein biologic therapies and oncology ... marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: ... the country,s Ministry of Food and Drug Safety ... (KTR) for MuGard, its oncology supportive-care treatment for ...
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) ... a United States patent has recently been allowed for ... , Entitled “Lipid Construct for Delivery of Insulin to ... related to the use of Diasome’s proprietary Hepatocyte Directed ... to more effectively reach the liver’s metabolic cells, called ...
(Date:3/30/2015)... March 30, 2015  Multiple new research abstracts suggest ... important health factors. From their impact on colon cancer ... effect on both gut health and vascular health, the ... our latest understanding of walnuts, inner workings. Running March ... , this annual meeting attracts an international audience of ...
Breaking Biology Technology:Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4
Cached News: